glp 1 agonist liraglutide FDA Approves First Generic Once-Daily Injection Generic Liraglutide (Victoza) Becomes First
Description
doi: 10.1016/S0140-6736(11)60814-3, PMID: [DOI] [PubMed] [Google Scholar] 2

Efficacy and safety of liraglutide added to capped insulin treatment in subjects with type 1 diabetes: the ADJUNCT TWO randomized trial
Metformin, resveratrol, and exendin-4 inhibit high phosphate-induced vascular calcification via AMPK-RANKL signaling

Stool softeners don't address the root cause
The FDA Adverse Event Reporting System (FAERS) contains reports of musculoskeletal complaints associated with GLP-1 use, but such reports do not prove causation and may reflect coincidental associations or other contributing factors

One of the major reasons is the high dropout rate, 11 possibly due to the nausea-related side effects and importantly the fact that these formulations are till date injectable
